Atara Biotherapeutics, Inc. (ATRA)
ValueMarkers Composite Index
DCF data not available
Atara Biotherapeutics, Inc. (ATRA) — VMCI valuation read
ATRA screens at VMCI 55/100, a 5-point gap above the Healthcare sector median (50). For a mid-cap Atara Biotherapeutics, Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.
ATRA has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.
**Investor frame.** Value: ATRA trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.3x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for Atara Biotherapeutics, Inc..
ATRA fell 1.6% over the trailing 7 days, with a +3.9% read on a 30-day basis.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.